FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications: FDA’s evaluation did not identify an increased risk of suicidal ideation or behavior with the use of GLP-1 RA medications
13 gennaio 2026
Leggi


